ATE250582T1 - Chinolinderivate als mek enzym-inhibitoren - Google Patents
Chinolinderivate als mek enzym-inhibitorenInfo
- Publication number
- ATE250582T1 ATE250582T1 AT00927492T AT00927492T ATE250582T1 AT E250582 T1 ATE250582 T1 AT E250582T1 AT 00927492 T AT00927492 T AT 00927492T AT 00927492 T AT00927492 T AT 00927492T AT E250582 T1 ATE250582 T1 AT E250582T1
- Authority
- AT
- Austria
- Prior art keywords
- carbon atoms
- optionally
- pyrimidinyl
- pyridinyl
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9910580.1A GB9910580D0 (en) | 1999-05-08 | 1999-05-08 | Chemical compounds |
| PCT/GB2000/001698 WO2000068199A1 (en) | 1999-05-08 | 2000-05-03 | Quinoline derivatives as inhibitors of mek enzymes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE250582T1 true ATE250582T1 (de) | 2003-10-15 |
Family
ID=10852989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00927492T ATE250582T1 (de) | 1999-05-08 | 2000-05-03 | Chinolinderivate als mek enzym-inhibitoren |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6638945B1 (de) |
| EP (1) | EP1178965B1 (de) |
| JP (1) | JP2002544194A (de) |
| KR (1) | KR20020000803A (de) |
| CN (1) | CN1350524A (de) |
| AT (1) | ATE250582T1 (de) |
| AU (1) | AU4589200A (de) |
| BR (1) | BR0010366A (de) |
| CA (1) | CA2371469A1 (de) |
| DE (1) | DE60005504T2 (de) |
| GB (1) | GB9910580D0 (de) |
| IL (1) | IL146319A0 (de) |
| NO (1) | NO20015447L (de) |
| TR (1) | TR200103185T2 (de) |
| WO (1) | WO2000068199A1 (de) |
| ZA (1) | ZA200108969B (de) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020054869A1 (en) | 2000-09-01 | 2002-05-09 | Han-Mo Koo | Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma |
| US7253184B2 (en) | 2000-11-02 | 2007-08-07 | Astrazeneca Ab | 4-Substituted quinolines as antitumor agents |
| US7067532B2 (en) | 2000-11-02 | 2006-06-27 | Astrazeneca | Substituted quinolines as antitumor agents |
| US6603005B2 (en) | 2000-11-15 | 2003-08-05 | Aventis Pharma S.A. | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them |
| US6602884B2 (en) | 2001-03-13 | 2003-08-05 | Aventis Pharma S.A. | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them |
| WO2002076496A1 (en) * | 2001-03-22 | 2002-10-03 | Van Andel Institute | Anthrax lethal factor inhibits tumor growth and angiogenesis |
| GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| GB0225579D0 (en) * | 2002-11-02 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
| WO2004112710A2 (en) * | 2003-06-17 | 2004-12-29 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß |
| ATE517091T1 (de) * | 2003-09-26 | 2011-08-15 | Exelixis Inc | C-met-modulatoren und verwendungsverfahren |
| WO2007132867A1 (ja) | 2006-05-15 | 2007-11-22 | Takeda Pharmaceutical Company Limited | 癌の予防及び治療剤 |
| CN101679357A (zh) * | 2007-05-09 | 2010-03-24 | 辉瑞大药厂 | 取代的杂环衍生物及其组合物和作为抗菌剂的药物用途 |
| KR102187034B1 (ko) | 2009-01-16 | 2020-12-04 | 엑셀리시스, 인코포레이티드 | 암 치료용 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
| EA201270051A1 (ru) * | 2009-06-25 | 2012-05-30 | Амген Инк. | Гетероциклические соединения и их применения |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| WO2012018638A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
| WO2012018639A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| EP3249054A1 (de) | 2012-12-20 | 2017-11-29 | Biomatrica, INC. | Formulierungen und verfahren zur stabilisierung von pcr-reagenzien |
| EP2956138B1 (de) | 2013-02-15 | 2022-06-22 | Kala Pharmaceuticals, Inc. | Therapeutische verbindungen und verwendungen davon |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| ES2831625T3 (es) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos |
| EP3007556B1 (de) | 2013-06-13 | 2020-05-20 | Biomatrica, INC. | Zellstabilisierung |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| MX355330B (es) | 2013-11-01 | 2018-04-16 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapeuticos y sus usos. |
| ES2891555T3 (es) | 2014-06-10 | 2022-01-28 | Biomatrica Inc | Estabilización de trombocitos a temperaturas ambiente |
| US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
| BR112018006873A2 (pt) | 2015-10-05 | 2018-11-06 | The Trustees Of Columbia University In The City Of New York | ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias |
| EP4242628A3 (de) | 2015-12-08 | 2023-11-08 | Biomatrica, INC. | Verringerung der erythrozytensedimentationsrate |
| CN106220560A (zh) * | 2016-07-27 | 2016-12-14 | 华侨大学 | 一种多取代喹啉衍生物的制备方法 |
| KR20190051010A (ko) | 2016-09-08 | 2019-05-14 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정형 및 그의 용도 |
| CA3036340A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| KR20230081932A (ko) | 2021-11-30 | 2023-06-08 | 주식회사 메타뷰 | 실내 위치 측위 정보를 모니터링하는 고온환경 스마트 팩토리 안전관리 시스템 및 그 방법 |
| KR102557537B1 (ko) | 2022-08-25 | 2023-07-20 | 김형미 | 개선된 통신 방식을 활용한 스마트 도어 제어 방법, 장치 및 시스템 |
| KR102498884B1 (ko) | 2022-11-04 | 2023-02-10 | 주식회사 레딕스 | 현장 작업자와 화물차 기사의 안전관리를 위한 안전관리 시스템 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE317376B (de) | 1961-07-10 | 1969-11-17 | Roussel Uclaf | |
| FR2077455A1 (en) | 1969-09-03 | 1971-10-29 | Aries Robert | 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials |
| US3936461A (en) | 1973-09-24 | 1976-02-03 | Warner-Lambert Company | Substituted 4-benzylquinolines |
| FR2498187A1 (fr) | 1981-01-16 | 1982-07-23 | Rhone Poulenc Sante | Procede de preparation d'amino-4 chloro-7 quinoleines |
| IL81307A0 (en) | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
| IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| US5409930A (en) | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5506235A (en) | 1991-08-02 | 1996-04-09 | Pfizer Inc. | Quinoline derivatives as immunostimulants |
| US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| AU7340096A (en) | 1995-11-07 | 1997-05-29 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| JP4386967B2 (ja) | 1996-07-13 | 2009-12-16 | グラクソ、グループ、リミテッド | プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物 |
| US6809097B1 (en) * | 1996-09-25 | 2004-10-26 | Zeneca Limited | Quinoline derivatives inhibiting the effect of growth factors such as VEGF |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| HUP0003731A3 (en) | 1997-07-01 | 2002-11-28 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
| ATE344791T1 (de) * | 1997-07-01 | 2006-11-15 | Warner Lambert Co | 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| UA72749C2 (en) | 1998-09-29 | 2005-04-15 | White Holdings Corp | Substituted 3-cyanoquinolines, a method for the preparation thereof (variants), pharmaceutical composition based thereon, a method for the treatment, inhibiting the growth or elimination of neoplasms and a method for the treatment, inhibiting progressing or elimination of polycystic kidney disease using them |
| SI2253620T1 (sl) | 1998-09-29 | 2014-06-30 | Wyeth Holdings Llc | Substituirani 3-cianokinolini kot inhibitorji protein tirozin-kinaz |
-
1999
- 1999-05-08 GB GBGB9910580.1A patent/GB9910580D0/en not_active Ceased
-
2000
- 2000-05-03 CA CA002371469A patent/CA2371469A1/en not_active Abandoned
- 2000-05-03 AT AT00927492T patent/ATE250582T1/de not_active IP Right Cessation
- 2000-05-03 DE DE60005504T patent/DE60005504T2/de not_active Expired - Fee Related
- 2000-05-03 WO PCT/GB2000/001698 patent/WO2000068199A1/en not_active Application Discontinuation
- 2000-05-03 BR BR0010366-7A patent/BR0010366A/pt not_active IP Right Cessation
- 2000-05-03 KR KR1020017014194A patent/KR20020000803A/ko not_active Application Discontinuation
- 2000-05-03 US US09/959,434 patent/US6638945B1/en not_active Expired - Fee Related
- 2000-05-03 JP JP2000617179A patent/JP2002544194A/ja active Pending
- 2000-05-03 AU AU45892/00A patent/AU4589200A/en not_active Abandoned
- 2000-05-03 TR TR2001/03185T patent/TR200103185T2/xx unknown
- 2000-05-03 IL IL14631900A patent/IL146319A0/xx unknown
- 2000-05-03 EP EP00927492A patent/EP1178965B1/de not_active Expired - Lifetime
- 2000-05-03 CN CN00807302A patent/CN1350524A/zh active Pending
-
2001
- 2001-10-30 ZA ZA200108969A patent/ZA200108969B/en unknown
- 2001-11-07 NO NO20015447A patent/NO20015447L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000068199A1 (en) | 2000-11-16 |
| TR200103185T2 (tr) | 2002-05-21 |
| IL146319A0 (en) | 2002-07-25 |
| ZA200108969B (en) | 2003-01-30 |
| EP1178965B1 (de) | 2003-09-24 |
| KR20020000803A (ko) | 2002-01-05 |
| US6638945B1 (en) | 2003-10-28 |
| DE60005504D1 (de) | 2003-10-30 |
| BR0010366A (pt) | 2002-02-13 |
| DE60005504T2 (de) | 2004-06-24 |
| CN1350524A (zh) | 2002-05-22 |
| NO20015447D0 (no) | 2001-11-07 |
| JP2002544194A (ja) | 2002-12-24 |
| CA2371469A1 (en) | 2000-11-16 |
| EP1178965A1 (de) | 2002-02-13 |
| GB9910580D0 (en) | 1999-07-07 |
| AU4589200A (en) | 2000-11-21 |
| NO20015447L (no) | 2001-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE250582T1 (de) | Chinolinderivate als mek enzym-inhibitoren | |
| ATE252561T1 (de) | Chinolinderivate als mek enzym-inhibitoren | |
| EE200100589A (et) | Kinoliini derivaadid MEK ensüümide inhibiitoritena | |
| HUP0104816A2 (hu) | 3-Azabiciklo[3.1.0]hexán-származékok mint ópiát receptor ligandumok és eljárás előállításukra | |
| TW342390B (en) | Carbocyclic and heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents | |
| EA200000731A1 (ru) | Альфа-аминоамидные производные, полезные в качестве анальгетических агентов | |
| RU95108387A (ru) | Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина | |
| HUP0004529A2 (hu) | VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk | |
| PL373888A1 (en) | 3-heteroaryl substituted 5-methyloxymethyl isoxazolines used as herbicides | |
| DE3462504D1 (de) | Indole-3-carboxamide derivatives | |
| NO163855C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive arylcyklobutylalkylaminer. | |
| DE3575140D1 (de) | Dreizyklische oxindole als antientzuendungsmittel. | |
| NO171786C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater | |
| SE8800863L (sv) | 3-(2-haloalkyl)-1,4-oxatiiner och 2-(2-haloalkyl)1,4-ditiiner och bahandling av leukemi och tumoerer daermed | |
| JO1676B1 (en) | Extra compounds indinol II | |
| HUP0001727A2 (hu) | Új 1-aza-2-alkil-6-aril-cikloalkán-származékok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények | |
| DE69301639D1 (de) | Tetrahydronaphtalenderivate, ihre Herstellung und ihre therapeutische Verwendung | |
| YU47530B (sh) | 6-supstituisani-heksahidrobenz cd indoli i postupak za njihovo dobijanje | |
| MX9802679A (es) | Derivados de ditiolan, su preparacion y su efecto terapeutico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |